Spots Global Cancer Trial Database for best available therapy (bat)
Every month we try and update this database with for best available therapy (bat) cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial) | NCT01243944 | Polycythemia Ve... | ruxolitinib tab... Best Available ... | 18 Years - | Incyte Corporation | |
| A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment | NCT04576156 | Myelofibrosis | Imetelstat Best Available ... | 18 Years - | Geron Corporation | |
| AOP2014 vs. BAT in Patients With Polycythemia Vera Who Previously Participated in the PROUD-PV Study. | NCT02218047 | Polycythemia Ve... | Pegylated-Proli... Best available ... | 18 Years - | AOP Orphan Pharmaceuticals AG | |
| An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib | NCT03952039 | Primary Myelofi... Post-Polycythem... Myelofibrosis | FEDRATINIB Best Available ... | 18 Years - | Celgene | |
| Controlled Myelofibrosis Study With Oral Janus-associated Kinase (JAK) Inhibitor Treatment-II: The COMFORT-II Trial | NCT00934544 | Myelofibrosis | Ruxolitinib Best Available ... | 18 Years - | Novartis | |
| Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial) | NCT01243944 | Polycythemia Ve... | ruxolitinib tab... Best Available ... | 18 Years - | Incyte Corporation | |
| KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment | NCT03662126 | Primary Myelofi... Post-Polycythem... Post-Essential ... | KRT-232 Best Available ... | 18 Years - | Kartos Therapeutics, Inc. | |
| Controlled Myelofibrosis Study With Oral Janus-associated Kinase (JAK) Inhibitor Treatment-II: The COMFORT-II Trial | NCT00934544 | Myelofibrosis | Ruxolitinib Best Available ... | 18 Years - | Novartis | |
| An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib | NCT03952039 | Primary Myelofi... Post-Polycythem... Myelofibrosis | FEDRATINIB Best Available ... | 18 Years - | Celgene | |
| An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib | NCT03952039 | Primary Myelofi... Post-Polycythem... Myelofibrosis | FEDRATINIB Best Available ... | 18 Years - | Celgene |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
